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Low carbohydrate diets have a promising mechanistic rationale in the treatment of cancer
with favorable preclinical data. The strongest data suggest synergistic effects of dietary
interventions with traditional cancer therapies. Recent prospective clinical trials suggest
that low carbohydrate diets are safely and feasibly added within a busy oncology clinic,
with hopeful additive effects in treatment enhancement.
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Cancer continues as the second leading cause of death across the United States, with an estimated
1.9 million new cancer cases expected in 2021 (1, 2). Cancer therapeutics also continues to progress.
According to the American Cancer Society statistics, as of 2018 the solid tumor death rate declined
to 128 per 100,000 age adjusted persons from a peak of 175 in 1991 (3). While this progress
should be lauded, the solid tumor death rate spanning back to 1930 was 190 per 100,000 age
adjusted persons—a minimal reduction in 60 years. Furthermore, cancer treatment can accelerate
aging, increasing the risk for comorbid conditions such as cardiovascular disease, diabetes, and
osteoporosis (4, 5). As such, nutrition is of increasing interest in the oncology clinic, not only to
decrease the risks of treatment sequelae, but also possibly to both prevent and treat disease. It is
estimated that 80,000 cancer cases per year could be prevented with an adequate diet alone (6–8).
In 1930, Otto Warburg published his seminal work revealing an altered metabolism in solid
tumors. Normal cells in high oxygen environments generate most of their cellular energy through
aerobic respiration, processing glucose through the mitochondria to produce ATP. Tumor cells,
on the other hand, shunt most glucose to lactate even in the presence of oxygen, called aerobic
glycolysis, or more commonly the “Warburg effect” (9). In a recent thought provoking discussion,
Vander Heiden et al. proposed the less efficient metabolism is adapted by tumor cells for the purpose
of biomass production (10). Leveraging this metabolic distinction is now the basis for nutrition in
oncologic research. Multiple dietary strategies have been employed, including the ketogenic diet
(KD), caloric restriction (CR), and intermittent fasting.
The ketogenic diet, originally developed for the treatment of intractable epilepsy, aims
to restrict carbohydrate and protein intake (11). Under low carbohydrate conditions,
generally achieved through minimal carbohydrate intake (<30 g), the liver produces betahydroxybutyrate (BHB) from fatty acids. Ketosis is also often achieved with some caloric
restriction and fasting regimens, as carbohydrates are subsequently also restricted below
these levels. BHB is a ketone body uniquely suited to bypass Warburg metabolism
given it cannot be metabolized back to glucose. It may therefore minimize tumor
production while supplying adequate energy to normal tissues, particularly the brain.
Indeed, some preclinical studies indicate some treatment efficacy with a KD therapy alone.
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respectively, but were closed due to poor accrual. Similarly,
the KETO-CARE trial (NCT03535701) is being conducted by
researchers from Ohio State University in advanced breast cancer
patients receiving chemotherapy. A separate trial from China
aims to examine whether a ketogenic diet can enhance the
response to irinotecan therapy in patients with recurrent or
metastatic breast cancer (23).
In 2020, the randomized, phase 2 DIRECT trial of stage II/III
breast cancer patients undergoing neoadjuvant chemotherapy
demonstrated several positive findings with the incorporation
of a fasting mimicking diet (24). The fasting mimicking
diet restricts calories and as such, simultaneously restricts
both carbohydrates and protein. A per-protocol analysis of
patients who were compliant with the diet in at least half
of their chemotherapy cycles revealed a significant increase
in grade 4/5 Miller and Payne pathological response rates
(OR 3.194, p = 0.031). Moreover, the more cycles completed
with the fasting mimicking diet, the greater the response to
therapy (p = 0.035). This effect was likely mediated through
ketosis with 93% of compliant patients demonstrating ketone
bodies in comparison to only 8% of non-compliant patients.
The fasting mimicking diet is currently being examined in
trials involving prostate cancer (NCT04292041), lung cancer
(NCT03700437), and in patients with any advanced cancers
undergoing chemotherapy (NCT04027478).
Additionally, a ketogenic diet is being investigated as a
potential strategy to decrease side effects of the anti-cancer
drugs. In 2008, researchers from the University of Southern
California showed that ketosis from short-term, 48–60 h fasting
provided protection to mice, but not to injected neuroblastoma
cells, against high dose etoposide chemotherapy (25). Despite
the high concentration of etoposide, which was three times the
upper limit used in humans, 96% of mice survived with fasting
while only 34% survived without it. These results prompted
the initiation of a fasting dose-escalation study for patients
undergoing chemotherapy (26). Twenty patients completed the
study in cohorts of 24, 48, and 72 h fasts. COMET assay results
indicated reduced DNA damage in leukocytes of patients who
fasted >48 h (p = 0.08). Study authors concluded that fasting for
72 h around chemotherapy was safe and feasible.
Since inflammatory pathway activation has been shown to
induce resistance to chemotherapy and metastatic proliferation,
dietary strategies to reduce inflammation are being explored
(27). Researchers at Thomas Jefferson University used a mouse
model for triple negative breast cancer, an aggressive breast
cancer variant, to demonstrate that chemotherapy induced
inflammation could be reduced with a low carbohydrate
approach involving caloric restriction (28).
Finally, a recent meta-analysis examined variables within six
clinical trials. Two were surgical, three delivered chemotherapy,
and one ADT. Two-hundred twenty-two patients comprised
the trials in total, with 153 completing the trials (79 lowcarbohydrate, 74 general diet). The included studies varied
significantly in design and reporting, with a very heterogeneous
group of cancer patients that make any results unreliable. Overall,
there was no evidence to support the beneficial effects of a
low-carbohydrate diet in anti-tumor therapy (29).

On the other hand, a recent meta-analysis of studies in mice
showed that a KD is unlikely to cure any disease outright (12).
Furthermore, tumors have shown to be metabolically flexible
by shifting their energy source in response to a change in
the nutrient environment (13, 14). Still, multiple preclinical
and clinical studies do show some efficacy of intervention by
synergizing with current cancer therapies.

CARBOHYDRATE RESTRICTION AND
CANCER CARE
Systemic Therapy
Immunotherapy
Immunotherapy has become a mainstay of cancer therapy.
Clinical trials have now demonstrated long-term increases
in overall survival using antibodies targeting cytotoxic Tlymphocyte-associated protein 4 (CTLA-4), programmed cell
death 1 (PD-1), or programmed death–ligand 1 (PD-L1), in
comparison to conventional chemotherapeutic agents (15–
17). However, not all patients respond to immunotherapy,
even when they share the same histology. Although causes
for differential responses are likely multifactorial, host
microbiota has been implicated as a significant factor. In
fact, a recently completed phase 1 feasibility study showed
that fecal microbiota transplant could convert anti-PD-1
non-responders to responders (18). These preliminary results
have now sparked a number of ongoing clinical trials of fecal
transplant in immunotherapy non-responders for a variety of
cancer types (NCT04729322, NCT03353402).
Since diet is a critical component of microbiota composition
(19), researchers from France recently reported preclinical data
bridging nutrition and cancer immunosurveillance (20). They
found that 3-hydroxybutyrate (3HB) supplementation or a KD
could induce response to immunotherapy when standard diet
conditions did not permit one. Mechanistically, they noted that
E. massiliensis was more abundant in the stools of ketogenic fed
mice compared to controls. This correlates well with human data
from the 1,000 patient UK PREDICT-1 study showing a positive
correlation between E. massiliensis and ketone levels (p < 0.05)
(21). 3HB also increased CD8+ T cells stimulated by immune
checkpoint blockade. Interestingly, they also found that effect of
3HB was enhanced when it was given intermittently. This would
likely permit easier application in the clinic through intermittent
fasting techniques.

Chemotherapy
Although immunotherapy has garnered significant attention,
chemotherapy remains the core of systemic cancer treatments.
Researchers from University of Iowa demonstrated that a
ketogenic diet may enhance responses to chemoradiation in
animal models of lung cancer (22). As a result of these and
other such preclinical studies, several ongoing trials are now
examining the integration of ketogenic diets with conventional
chemotherapy agents. The KETOLUNG (NCT01419587) and
KETOPAN (NCT01419483) trials based out of University of
Iowa, aimed to examine the feasibility of the ketogenic diet
with chemotherapy and radiation for lung and pancreas cancers,
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preclinical data, a prospective feasibility trial then enrolled two
patients with Stage II/III pancreatic cancer and seven patients
with stage III (non-operable) or IV (oligometastatic) non-small
cell lung cancer (NSCLC) undergoing chemoradiation with the
addition of the same 4:1 KD. The KD was poorly tolerated in this
cohort with only 3 of the combined 9 patients completing the trial
due mostly to poor compliance.
In a small German series, six patients consumed a selfadministered KD during radiotherapy in a prospective manner
(39). There were no diet related treatment toxicities and no
negative effects on any blood parameters noted in the study.
They too concluded the diet was safe and feasible. The same
group proceeded with the KETOCOMP trial, analyzing the body
composition changes of a cohort of 59 breast cancer patients
undergoing radiation therapy. Twenty-nine received a ketogenic
diet and 30 remained on their standard diet with no changes (40).
The ketogenic diet caused initial water loss, with significant losses
in body weight and fat mass, without substantial changes in fat
free or skeletal muscle mass. The patients’ quality of life remained
stable with the dietary intervention.
In an intracranial bioluminescent mouse model of glioma,
mice were fed a 4:1 (fat:protein+carbohydrate) KD vs. standard
chow. When compared directly without additional treatment, the
mice on the KD chow lived statistically longer, with a median
survival of 28 days vs. 23 (p = 0.005). However, when the KD was
combined with radiation, a synergistic effect occurred increasing
the median survival significantly (p = 0.0001) and apparently
curing nine out of eleven animals of their disease (41). To study
glioblastoma multiforme (GBM) in the clinic, a retrospective
analysis at the University of Pittsburgh analyzed 53 patients with
GBM undergoing concurrent chemoradiation, six of whom were
also on a ketogenic diet (42). The diet was well-tolerated with no
grade III toxicities, no episodes of symptomatic hypoglycemia,
lower average glucose even in the presence of steroids, and four
out of six patients alive at a median follow-up of 14 months.
An experience from Cincinnati reviewed 29 patients with
grade II-IV gliomas who were prescribed a modified Atkins diet
(MAD), a modified low carbohydrate diet less restrictive than
the classical KD (2:1 vs. 4:1) (43). These patients underwent
radiation therapy plus or minus chemotherapy depending on
grade. Of the 29 patients, 19 had GBM. All 29 patients achieved
ketosis during the study period, defined in this study by 0.5
mmol/L, with 23/29 achieving 1 mmol/L. Only one patient
stopped the diet early before the 6 week course of radiation. No
grade III or grade IV toxicities were observed. In addition, the
study analyzed an exploratory endpoint of pseudoprogression
(PSP). One hypothesis for the mechanism of PSP is radiation
sensitization. In this cohort, of the 19 patients with GBM, 11
(58%) developed PSP after combined treatment with MAD and
chemoradiotherapy. The authors concluded the diet was safe and
feasible, and they speculated that, given the percentage of patients
with PSP were increased compared to historical controls, perhaps
MAD provides a sensitizing effect to radiation therapy.
There are six ongoing trials open studying the effects of
the KD in the treatment of GBM. Michigan State University is
recruiting 16 patients with GBM for concurrent and adjuvant
KD along with standard of care surgery, chemoradiation, and

The PI3K-Akt-mTOR pathway regulates a number of critical
cellular functions including mRNA translation, autophagy
and metabolic processes such as lipogenesis (30). Although
abnormalities in this pathway have been implicated in breast,
colorectal, hematologic and many other cancers, drugs targeting
the pathway, such as PI3K inhibitors, have thus far proven
clinically ineffective (31). Researchers from Cornell hypothesized
that drug induced hyperinsulinemia may be limiting the
therapeutic impact of these agents. They conducted a series of
experiments using PI3K inhibitors in various mammalian tumor
models. Study results demonstrated that resistance to PI3K
inhibitors is mediated through reactivation of the PI3K-mTOR
signaling pathway by insulin feedback (32). This preclinical data
was consistent with clinical studies in which hyperglycemia was
exacerbated in patients with insulin resistance, and resulted
in discontinuation of PI3K inhibitor therapy. The group from
Cornell went a step further and examined whether resistance
to PI3K inhibitors could be suppressed through dietary or drug
interventions limiting insulin feedback. These strategies included
the ketogenic diet as well as sodium-glucose co-transporter
2 (SGLT2) inhibitor drugs used in diabetics. The addition of
either intervention resulted in enhanced response to P13K
inhibitors. Although clinical trials incorporating these strategies
remain forthcoming, ongoing studies of PI3K inhibitors have
restricted diabetic participants as a result of these findings
(NCT01623349, NCT03213678).

Hormonal Therapy
Hormonal factors are implicated in carcinogenesis and
consequently, are often targeted in cancer therapy. As an
example, testosterone is highly implicated in prostate cancer
growth and development (33). Anti-androgen drugs are therefore
employed as anti-cancer therapies to lower testosterone levels.
Although effective, these drugs induce hyperglycemia and
hyperinsulinemia (34, 35), which increase steroidogenesis
and androgen levels, and ultimately cause resistance to these
medications (36, 37). There are two trials out of the University
of Maryland (NCT03194516) and Cedars-Sinai (NCT03679260)
currently analyzing carbohydrate restricted diets in the setting
of men with prostate cancer on active surveillance to study
progression prior to cancer therapy. As with prostate cancer,
many patients with breast cancer undergo hormonal therapy
as part of their treatment. Researchers from Vanderbilt are
currently conducting a trial examining the feasibility of a 2-week
ketogenic diet intervention with letrozole based hormonal
therapy prior to surgery (NCT03962647). They hope to examine
the effect of the diet on PI3K signaling.

Radiation Therapy
Preclinical models suggest a potential synergistic effect of
carbohydrate deprivation and radiation therapy. A study out
of the University of Iowa treated mice with pancreatic cancer
xenografts fed either a ketogenic chow or standard rodent chow,
all treated with radiation (12Gy in 2Gy fractions). The mice on
the 4:1 KD chow lived longer (p = 0.05) with slower tumor
growth (p = 0.05) and decreased weight loss (38). Given this
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tumors. While promising, these findings should be taken with
caution given the relatively small number of patients and the
low number of events (50). Additionally, though in the fed arm
they were loaded with a carbohydrate diet, further analyses are
required to determine whether the benefit seen in the fasting arm
is secondary to carbohydrate restriction, protein restriction, or
caloric restriction/being in a fasting state.
Currently, there are three studies analyzing low carbohydrate
diet with a ketogenic protocol in the perioperative setting.
These include a multi-institutional study out of Memorial Sloan
Kettering randomizing newly diagnosed endometrial cancer
patients to KD vs. standard diet in the prior to surgery
(NCT03285152). A study based in France will assess a KD
vs. protein restricted diet 10 days prior to surgery for breast
cancer (NCT04469296). Finally, a study in Seoul, South Korea
(NCT03510429) will analyze a ketogenic supplement after
pancreaticobiliary cancer resections.

adjuvant chemotherapy (NCT01535911). UC Health Cincinnati
(NCT03451799), Cedars Sinai Medical Center (NCT03451799),
the Mid-Atlantic Epilepsy and Sleep Center (NCT02302235),
Waikatu Hospital (NCT0430869), and the Guangzhao Medical
University (NCT03160599) all have feasibility trials open
analyzing KD in conjunction with standard of care therapies for
GBM. The University of Liverpool recently completed a trial with
using the KD in the adjuvant setting but has not yet reported
results (NCT03075514).

Surgical Oncology
The relationship between carbohydrate restriction and surgical
oncology has not been investigated as rigorously. In fact,
carbohydrate loading is now a central component of the
enhanced recovery after surgery (ERAS) perioperative care
pathways to mitigate the stress response to surgery (44).
The stress response consists of complex neurohormonal
and inflammatory responses that results in activation of
the sympathetic nervous system, and secretion of cortisol,
vasopressin and glucagon, leading to catabolism of skeletal
muscle and insulin resistance (45). As insulin is an anabolic
hormone, the induced insulin resistance promotes a catabolic
state (46). Animal models have demonstrated a heightened stress
response following trauma when in a fasting state, whereas a fed
state blunted the stress response (47). Improved postoperative
insulin sensitivity has been correlated with a decrease in length of
hospital stay and postoperative major complications, therefore,
the ERAS society recommends intake of clear fluids until 2 h
prior to anesthesia induction (48). A large meta-analysis which
included 1,976 patients demonstrated shorter hospital stay,
shortened time to flatus passage, and increased postoperative
insulin sensitivity, though it did not demonstrate a significant
difference in the rate of postoperative complications (44).
While there appears to be a clinical benefit to preoperative
carbohydrate loading regarding peri-operative metrics, a
preoperative carbohydrate load may be counterproductive
from an oncologic standpoint in the case of the surgical
removal of malignancies. An undesired consequence of surgical
manipulation is tumor seeding and cancer cells being pushed into
circulation. Following excision, circulating tumor cells following
excision are correlated with worse survival (49). Carbohydrate
loading may promote an environment where these cells can
become a viable metastatic focus. A phase III randomized trial
was conducted in Norway comparing the effects of preoperative
carbohydrate loading vs. a standard fasting preoperative protocol
in patients with operable breast cancer. Thirty seven patients
were allocated to the carbohydrate arm and 43 to the fasting arm,
with 31 patients in the carbohydrate arm and 35 in the fasting
arm receiving the allocated intervention. Results indicated that
for patients with estrogen receptor (ER) positive breast cancer,
70% of fed patients had high proliferation (defined as an mitotic
activity index ≥10) as compared to 30% in the fasting group (p =
0.038). The carbohydrate intervention (CI) group demonstrated
an increase in serum insulin and c-peptide. Relapse free survival
was improved for ER positive patients in the fasting group as
compared to the fed group (97% vs. 71%, p = 0.012), though
on Kaplan-Meir analysis this was demonstrated only in T2
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CONCLUSION
Early results from carbohydrate restriction in both preclinical
and clinical investigations are mixed. The significant increase
in clinical trials examining this strategy reflects a growing
interest in this approach for virtually all cancer subtypes.
There is currently a paucity of evidence to suggest that a
low-carbohydrate diet amongst a general population of cancer
patients will improve cure rates. However, there is data to suggest
efficacy when combined with some treatment modalities and in
certain histologies. Additionally, strategies involving potential
replacement or deferment of standard-of-care treatments with
metabolic monotherapy remain limited to case studies and
smaller, pilot trials (NCT03194516) (51). Though intriguing,
more data is needed to validate such an approach.
Future directions of carbohydrate restriction during cancer
therapy are likely to focus on hormonally sensitive tumors such
as breast cancer and prostate cancer where obesity is a known
risk factor. For other cancers, it may also be prudent to target
patients who are metabolically unhealthy, as improving baseline
metabolic health may contribute to treatment response in this
population. Current studies involving epigenetics and precision
medicine will further aid in the identification of patients who may
benefit most from such approaches. Lastly, and perhaps most
critically, a biomarker is needed to permit better comparisons
of efficacy and protocol adherence within studies. One such
candidate is the glucose-ketone index, which has shown utility
in patients with high grade gliomas (52). Given the potential
confounding impact of diet and metabolism on cancer, all studies
examining cancer therapeutics or prevention would benefit from
inclusion of such a biomarker.
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